Serena M.
- Country
- Italy
- Department
- Dipartimento di Oncoematologia, UOC oncologia medica
Research Overview
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Elacestrant and Everolimus in ER+/HER2-, ESR1-Mutated Advanced Breast Cancer Post-Endocrine and CDK4/6 Inhibitors
- Phase II Randomized Study of Trastuzumab Deruxtecan vs. CDK4/6 Inhibitor-Based Endocrine Therapy in HR-Positive, HER2-Low/Ultra-Low Advanced Breast Cancer
Data & Insights
Has run more than one trial at 35 of 128 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in advanced therapeutic approaches for estrogen receptor-positive breast cancer, with particular focus on treatment strategies for patients who have developed resistance to standard therapies.
- ESR1-mutated breast cancer
- Advanced breast cancer management
- Hormone receptor-positive disease
The research involves innovative combination approaches for patients whose disease has progressed following endocrine therapy.
Targeted Therapies
The investigator concentrates on developing treatment solutions for HER2-negative breast cancer patients, exploring novel therapeutic combinations to overcome treatment resistance.
- Endocrine therapy resistance
- CDK4/6 inhibitor treatments
- Combination therapy approaches
Their work addresses critical needs in treating hormone receptor-positive breast cancer that has become resistant to standard treatments.
Clinical Innovation
The investigator's expertise extends to evaluating novel therapeutic combinations for advanced breast cancer, particularly focusing on treatments for patients with specific genetic mutations.
- Biomarker-driven therapies
- Treatment resistance mechanisms
- Advanced disease management
Their research explores innovative treatment strategies for patients with specific molecular alterations in breast cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.